Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.69 |
| ▸ | OPRL1 | P41146 | 14/20 | 0.69 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28667548 | 0.93 | OPRM1 (0.80) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL9837438 | 0.93 | OPRM1 (0.75) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL30364082 | 0.92 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL19691160 | 0.92 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL13361543 | 0.92 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL828730 | 0.88 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL5427154 | 0.88 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL19410694 | 0.88 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL29809539 | 0.88 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL10316251 | 0.88 | OPRM1 (0.69) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107501099-A | The adjusting control agent of ATP combination cassette transporters | 沃泰克斯药物股份有限公司 | 2017-12-22 | — | — | CN | disclosed |
| CN-104788328-B | The adjusting control agent of ATP combination cassette transporters | 沃泰克斯药物股份有限公司 | 2017-09-12 | — | — | CN | disclosed |
| CN-103641765-B | ATP-combines the adjusting control agent of cassette transporters | 沃泰克斯药物股份有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-101935301-B | Modulators of ATP-binding cassette transporters | VERTEX PHARMA | 2013-10-16 | — | — | CN | disclosed |
| EP-2556070-A1 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'- INDOLIN]-2'-ONES | University Health Network (CA) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011123947-A8 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'- INDOLIN]-2'-ONES | UNIVERSITY HEALTH NETWORK (CA) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011123947-A1 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'- INDOLIN]-2'-ONES | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| EP-2231668-A1 | CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| CN-101006076-B | Modulators of ATP-binding cassette transporters | VERTEX PHARMA | 2010-09-29 | — | — | CN | disclosed |
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009086139-A1 | CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| CN-101006076-A | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2007-07-25 | — | — | CN | disclosed |
| US-7205328-B2 | Aids viricide | IRM LLC (BM) | 2007-04-17 | — | — | US | disclosed |
| US-20040152755-A1 | Oxindoles with anti-HIV activity | IRM LLC, A DELAWARE LLC (BM) | 2004-08-05 | — | — | US | disclosed |
| WO-2004037247-A1 | OXINDOLES WITH ANTI-HIV ACTIVITY | IRM LLC (BM) | 2004-05-06 | — | — | WO | disclosed |
| WO-1999058525-A1 | INDOLE DERIVATIVES AS 5-HT2A LIGANDS AND AS SEROTONINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY LIMITED (GB) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, EIF2AK2, MAVS | OPRM1 2225/4885OPRK1 1742/4885OPRL1 3976/4885 |
| US-20040152755-A1 | Oxindoles with anti-HIV activity | IDO1, API5, NFATC1 | OPRM1 62/4885OPRK1 16/4885OPRL1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.